EXICURE, INC. Restricted Cash and Cash Equivalents
EXICURE, INC. (XCUR) had Restricted Cash and Cash Equivalents of $608.00 thousand as of 2024-09-30, per its 10-Q filed 2024-11-14.
Financial Statements › Balance Sheet › Assets › Restricted Cash and Cash Equivalent
us-gaap:RestrictedCashAndCashEquivalents · last filed 2024-11-14
- 2024-09-30: Restricted Cash and Cash Equivalents $608.00K.
- 2024-06-30: Restricted Cash and Cash Equivalents $872.00K.
- 2024-03-31: Restricted Cash and Cash Equivalents $1.20M.
- 2023-12-31: Restricted Cash and Cash Equivalents $1.20M.
| Period end | Restricted Cash and Cash Equivalents |
|---|---|
| 2024-09-30 | $608.00K 10-Q · filed 2024-11-14 |
| 2024-06-30 | $872.00K 10-Q · filed 2024-08-13 |
| 2024-03-31 | $1.20M 10-Q · filed 2024-06-17 |
| 2023-12-31 | $1.20M 10-Q · filed 2024-11-14 |
| 2023-09-30 | $1.20M 10-Q · filed 2024-05-16 |
| 2023-06-30 | $1.20M 10-Q/A · filed 2024-06-06 |
| 2023-03-31 | $1.20M 10-Q/A · filed 2024-06-06 |
| 2022-12-31 | $1.20M 10-Q/A · filed 2024-06-06 |
| 2022-09-30 | $1.20M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $1.20M 10-Q · filed 2022-08-15 |
| 2022-03-31 | $1.20M 10-Q · filed 2022-05-16 |
| 2021-12-31 | $9.20M 10-K · filed 2023-03-27 |
| 2021-09-30 | $1.20M 10-Q · filed 2021-11-19 |
| 2021-06-30 | $1.20M 10-Q · filed 2021-08-12 |
| 2021-03-31 | $1.20M 10-Q · filed 2021-05-12 |
| 2020-12-31 | $1.20M 10-K · filed 2022-03-25 |
| 2019-12-31 | $0.00 10-K · filed 2021-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |